Clínic Barcelona

Aelix Therapeutics gets €11.5M for therapeutic HIV vaccine

Aelix Therapeutics, a drug development company created from the HIVACAT project and specialized in the discovery and development of immunotherapies against HIV infection, has completed a funding round of €11.5 M. Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a syndicate of new investors including Johnson & Johnson Innovation – JJDC Inc. (“JJDC”), and Caixa Capital Risc, the venture capital division of Spain’s leading financial group, ‘la Caixa’. Doctors Josep M. Gatell, head of the Infectious Diseases Department at Hospital Clínic and IDIBAPS, Bonaventura Clotet and Christian Brander, from the Institute for AIDS Research (IrsiCaixa), and Jordi Naval, are co-founders of the company and in charge of this project.